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Abstract
Background: Glanzmann thrombasthenia (GT) is a rare autosomal recessive abnormality of platelet aggregation
with quantitative and/or qualitative abnormality of αIIbβ3 integrin. The αIIbβ3 is a platelet fibrinogen receptor,
which is required for platelet aggregation, firm adhesion, and also spreading.
The disease is more prevalent in the populations with a higher rate of consanguineous marriages as in some
Middle Eastern populations including Iraq, Jordan, and Iran. Different types of mutations in ITGA2B and ITGB3 genes
have been previously reported to cause the disease.
Result: In this study, 16 patients with the clinical diagnosis of GT were studied. Direct sequencing of the exons and
exon-intron boundaries of the above genes revealed mutations in 14 patients (detection rate: 87.5%). Briefly, out of
fifteen types of identified mutations, 14 were novel. Seven mutations in the ITGB3 gene included 4 missense [c.2T > C,
c.155 G > T, c. 538 G > A, c.1990 G > T], one nonsense mutation [c.1303 G > T], a small deletion [c.1656_1658delCTC] and
a deletion of one nucleotide [c.401delA]. Mutations in the ITGA2B were 8 different mutations consisting 2 missense
[c.286 T > A, c.842 C > T], 2 deletions [c.1899 del T, c.189-319_236del], an insertion [c.1071_1072insG] and one splice site
mutations [c.409–3 C > G], one synonymous mutation that might alter the normal splicing process [c.1392 A > G] and a
nonsense mutation [c.1555 C > T].
The causative mutation in 2 patients remained unknown. Using long-range PCR and sequencing, we found a rather
large deletion. The break point of this deletion covers 319 nt from the last part of the first intron and 48 nt from the
beginning of the second exon of ITGA2B gene. The deletion was also detected in two unrelated patients with the
same ethnicity. In addition, in silico analyses of novel mutations were performed.
Conclusion: There was no recurrent mutation in the studied population. This may be due to either small sample size
or the heterogeneity of the studied population.
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Introduction
Glanzmann thrombasthenia (GT, OMIM: 273800) is a
rare inherited disorder of platelet function, caused by
quantitative or qualitative defects of the platelet mem-
brane glycoprotein (GP) IIb-IIIa (αIIbβ3) complex [1]. Pa-
tients have lifelong mucosal bleeding and may require
platelet transfusions for severe bleeding episodes. Bleeding
complications are also frequent after dental extraction,
surgery, or delivery [2]. GT is a rare disorder worldwide
but is relatively frequent in populations such as Iraqi, Jews,
Jordanian Arabs, Iran, Palestine, South Indians and French
Gypsies with a high frequency of consanguineous mar-
riages [3, 4].
The molecular basis of GT is linked to quantitative and/
or qualitative abnormalities of αIIbβ3 integrin that mediates
binding of the adhesive proteins to attach aggregating plate-
lets and ensure thrombus formation at sites of injury in
blood vessels. GT is classified into 3 subtypes, depending
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on the level of αIIbβ3. Affected individuals show mucocuta-
neous bleeding with the absent of platelet aggregation in re-
sponse to all physiologic stimuli. They show normal platelet
count and morphology. In addition, platelet αIIbβ3 defi-
ciency or dysfunction should always be confirmed.
Laboratory tests in severe GT show no platelet aggrega-
tion in response to all physiologic agonists and show re-
duced or absent clot reaction [5]. Patients with type I or
classical GT have a virtual absence of αIIbβ3 complex (< 5%
of normal). In type II GT, patients have up to 25% of the
normal level of the complex. In the variant type, αIIbβ3 level
is near normal but functionally impaired, leading to defect-
ive binding of fibrinogen [6, 7].
The αIIbβ3 complex integrin is encoded by ITGA2B and
ITGB3 genes (GPIIb and GPIIIa respectively). In brief, integ-
rin synthesis occurs in the megakaryocytes with the αIIbβ3
complex formation in the endoplasmic reticulum (ER). The
pre-GPIIb-IIIa complex is then transported to the Golgi ap-
paratus, where sugar modification and cleavage of GPIIb
into a heavy (M, 125,000) and light chain (M, 23,000) takes
place [5]. GPIIb heavy and light chains remain covalently
linked by a single disulfide bond. Following these processing
events within the Golgi, the mature GPIIb-IIIa complex is
then transported to the cell surface, where it exists in a rest-
ing state awaiting cellular activation. Noncomplexed or
incorrectly folded gene products fail to undergo processing
in the Golgi apparatus and are rapidly degraded
intra-cellularly.
A continually updated mutation database is available
on the sinaicentral.mssm.edu/intranet/research/glanz-
mann website [3, 4]. The molecular and functional
characterization of the mutations has provided import-
ant insights to the better understanding of the biosyn-
thesis and structure-function relationships of the
αIIbβ3complex with the disease. It also adds important
knowledge about the biology of other molecules of the
integrin family [8, 9].
Genetic testing in GT patients is very important in the
quality of life of the affected individuals and it facilitates
prenatal diagnosis (PND) or pre-implantation genetic diag-
nosis (PGD) for at-risk families. The identified mutations
will span the current database of the mutations of GT.
We aimed at identifying mutations underlying GT in Iran-
ian patients from different parts of Iran. Most of the docu-
mented mutations were single nucleotide substitutions but
large deletions are rarely reported. This study is reporting a
novel large deletion of 367 bp in ITGA2B gene encompass-
ing the last part of the first intron and the beginning part of
the second exon of the gene.
Material and methods
Patients’ description
Sixteen unrelated families with the diagnosis of GT were
investigated for the ITGA2B and the ITGB3 genes
mutations. The patients were referred to Medical Genet-
ics Laboratory of Dr. Zeinali by hematologists. They
were referred from the different parts of the country
covering different races and ethnicities. Diagnosis of GT
was based on the clinical picture of recurrent nasal
hemorrhage, purpura, prolonged bleeding time (BT) and
normal platelet count. Clinical features of each patient
are reported in Table 1. Kawsar Human Genetics Re-
search Center (KHGRC) ethical committee approved the
research proposal.
Genetic counseling was performed and all participants
signed informed consent forms. 10 ml of peripheral
blood of the patients and their parents were provided in
tubes containing EDTA as an anticoagulant. Genomic
DNA were extracted by salting out method [10].
Molecular genetic study
Genetic study of the patients was conducted using direct
sequencing of the entire coding and exon-intron bound-
aries of the ITGA2B and the ITGB3 genes [3, 4]. Primer
sequences are available upon request. PCR amplification
was performed in a total volume of 25 μl containing
2.5 μl of 10X buffer (Kawsar Biotech Co., Tehran, Iran,
KBC), 2.5 μl DMSO (Sigma-Aldrich, USA), 0.96 mM
dNTPs (KBC), 4 mM MgCl2 (KBC), 6 pmol of forward
and reverse primers, 1 U Taq polymerase (KBC), and 30
ng of genomic DNA as a template. The thermocycling
consisted of 1 cycle of initial denaturation at 95 °C for 5
min, followed by 30 cycles of 1 min denaturation at 95 °
C, 1 min annealing at 64 °C, and 1min extension at 72 °
C, following a final extension at 72 °C for 10 min and
storing the PCR product in 4 °C.
Sequencing.
PCR products were directly sequenced using BigDye
Terminator kit (Thermo Fisher Scientific, USA, TF)
according to the manufacturer’s protocol. Then the sam-
ples were run on an ABI3130XL Genetic Analyzer (TF).
Sequences were compared with human genomic and
cDNA sequences of the genes with the accession num-
bers of ITGA2B (NM: 000419, NC:000017) and ITGB3
(NM:000212, NC:000017). Mutations nomenclature was
conducted according to the recommendations of Human
Genome Variation Society [11].
Characterization of a deletion breakpoint
Systematic failure to amplify the 2nd and 3rd exons
(since these exons are amplified together) of the ITGA2B
suggested deletion of these two exons. To exactly deter-
mine the breakpoint, PCR- amplification with forward
(F) of 2nd exon (2–3) and reverse (R) of 4th exon (3–4)
was carried out. Primer sequences are listed below:
ITGA2B (2–3) F: GTCTGTGAGGTGTCATTGAGGA.
ITGA2B (3–4) R: GCTTCACAGTAACGCTTGTCC.
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To find out the break point of this deletion, primer
walking and subsequent sequencing were applied. The
reaction mixture and PCR parameters were as above.
In order to check the frequency of novel missense var-
iants, we performed ARMS-PCR in 100 ethnically
matched healthy controls. Sequences of ARMS primers
for these tests can be provided upon request. Bioinfor-
matics analysis was also performed to elucidate the clin-
ical significance of the identified variants. We used
available online bioinformatics tools such as SIFT and
PolyPhen Project to see the impact of missense variants
on disease pathogenicity. Also, Mutation Taster was used
for deletion and insertion variants [12].
Results
The study included sixteen unrelated families with the
diagnosis of GT. As it was expected most of the patients
were the result of consanguineous marriages (14/16 fam-
ilies, 87%). Sequencing analysis revealed totally 15 differ-
ent mutations in the ITGB3 and the ITGA2B genes
(Table 1). All identified mutations were homozygous
except one in the ITGB3, which was in the form of com-
pound heterozygous. Mutations in the ITGB3 gene con-
sist 7 different mutations including 4 missense
mutations [c.2T > C, c.155 G > T, c. 538 G > A, c.1990
G > T], a nonsense mutation [c.1303 G > T], one small 3
nt deletion [c.1656_1658delCTC] and a deletion of a sin-
gle nt [c.401delA]. Interestingly all identified mutations
in this gene were novel (Table 1).
Mutation scanning in the ITGA2B revealed 8 different
mutations including an insertion [c.1071_1072insG], 2
missense mutations [c.286 T > A, c.842 C > T], a nonsense
mutation [c.1555 C > T], 2 deletions [c.189-319_236del,
c.1899 del T], one splice site mutation [c.409–3 C >
G] and one synonymous mutation that might alter the
normal splicing process [c.1392 A >G].
The identified variants were heterozygote in parents
and were not present as homozygote in their healthy
members of the family as expected in cases where muta-
tions are deleterious. To further confirm the pathogen-
icity of the missense variants, we checked the mutation
in 100 random people and they were normal which sup-
ports the pathogenicity of the novel variants.
In a family, while sequencing exons 2 and 3, we could
not get any band in the patients suggesting that theses
exons may be deleted. In order to characterize the dele-
tion breakpoints, primer walking and sequencing were
performed. While the size of DNA fragment in normal
cases was nearly 1500 bp as expected but the size of
DNA product from the patient was around 1200 bp.
Subsequent sequencing of this fragment confirmed dele-
tion of 367 bp covering 319 nt from intron 1 and 48 nt
in the second exon (Fig. 1).
Discussion
GT is a rare congenital bleeding syndrome, which re-
sults in deficient platelet aggregation due to the ab-
sence or dysfunction of the fibrinogen receptor αIIbβ3
[12]. However, GT is rare worldwide but is relatively
frequent in inbred populations such as Iraqi-Jews, In-
dians, and Arabs in Jordan, Israel, and Saudi Arabia.
The exact number of GT patients in Iran has not been
clearly reported. But it seems that the disease incidence
will be higher from the estimated 1 in 200,000 in the
US population. Because Iran is a country with nearly
38.4% rate of consanguineous marriage and at the other
hand autosomal recessive mode of inheritance of the
disease will add to the number of patients [13]. To the
best of our knowledge, this study is the first compre-
hensive study on the molecular aspects of GT in Iran-
ian population. Needless to say there is another similar
study carried out by Kazemi et al. [14] on Iranian popu-
lation but only three deleterious mutations have been
reported out of 20 families affected with GT. However,
none of the mutations reported by them is repeated in
our study.
In Table 1 we have provided types of mutations and
their effects at the amino acid level. Further in silico
analysis was performed (Table 2) to find how these
changes can be pathogenic. Obvious ones will not be
discussed.
The first patient (Table 1) with c.2T > C point mu-
tation which is located at the very beginning of the
first exon of the ITGB3 gene (β3 subunit,) will change
the methionine to threonine. Initiator methionine is
very important for the initiation of protein synthesis.
Regarding the third patient with c.401delA mutation
in the ITGB3, and based on mutation taster prediction
[15] it is disease causing change. The fourth patient with
c.1303G > T [p. Glu435Ter] mutation, causes change of
glutamic acid to a termination codon leading to prema-
ture stop codon with only 434 residues which most
probable will not function properly. The other patient
had c.155 G > T mutation in the ITGB3 gene, changing
cysteine into phenylalanine. The wild-type residue is in-
volved in a cysteine bridge formation, which is import-
ant for the stability of the protein. Only cysteine can
make these types of bonds, so the mutation causes loss
of this interaction and will have a severe effect on the
3D-structure of the protein. Together with the loss of
the cysteine bond, the differences between old and new
residue can cause destabilization of the structure [16],
This prediction is also supported by SIFT and Polyphen
results. The c. 538 G > A [p. Gly180Arg] mutation in the
ITGB3 changes glycine into arginine and introduces an
amino acid with different properties that can disturb this
domain and abolish its function. Because the wild-type
residue, glycine, is the most flexible of all residues.
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Mutation of this glycine can abolish this function. This
flexibility might be necessary for the protein’s function
and by this mutation the torsion angles for this residue
are unusual [16]. This prediction is also compatible with
the SIFT and Polyphen prediction (Table 2).
The deletion of T nucleotide in exon 19 of ITGA2B gene
(i.e. c.1899 del T [p. Cys633TrpfsTer17]) causes a frameshift
in protein structure. HSF (Human splice finder) predicted
that this frameshift created an exonic ESS site that has a po-
tential to alter the splicing [17]. Regarding c.409–3 C > G
Fig. 1 The figure shows schematic representation of the DNA sequences from the joining parts of the first and third exons. If this is the case,
then AG nucleotides from the first exon and the G from the third exon will join together. [The orange arrows show the expected joining
between exon1 and 3, which leads to a frameshift and a truncated protein. Lowercase red letters indicates the deleted part. The upper letters in
black color show the intronic regions and upper letters in yellow and blue boxes show the exonic regions. Blue arrows show the start and the
end of the deleted part. The green arrow indicates the first nucleotide at the beginning part of the second exon]
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and c.1392 A > G mutations in the ITGA2B which occurred
near the potential splice sites of the protein, this can alter
the wild type acceptor and donor site respectively. The
c.189-319_236del mutation at ITGA2B gene leads to the
elimination later part of the intron one and the beginning
part of second exon. This deletion, therefore, deletes the
splice acceptor site. This in turn should cause deletion of
the entire exon 2 because there is no alternative splice site
within the remaining part of exon 2 and therefore the
remaining part of this exon will be eliminated via splicing of
intron 1 (donor site), joining of exon1 and exon3. Therefore
it is expected that through this splicing the exon 1 will be
joined with exon 3. Figure 1 shows that if this would be the
case then amino acids 63rd to 103rd will be lost and a
frameshift would be resulted. The frameshift mutation leads
to a truncated protein which loss of function would be re-
sulted. Since we could not obtain fresh blood from the pa-
tient to perform RNA analysis, the above conclusion can be
provided. However, whatever the consequence at the mo-
lecular level, we can claim that resulting effect at the protein
level is having damaging effect on the patient.
It should be added that the identified variants were
not present in the single nucleotide polymorphism data-
base (Exome Variant Server, http://evs.gs.washington.
edu/EVS/).
Regarding phenotype-genotype correlation, more stud-
ies with larger sample size is recommended.
It is interesting to see so many novel mutations in a
rather small number of families (14/16) indicating sev-
eral independent founder mutations. If we combine
other mutations reported by others (Kazemi et al.) with
ours it might become even more interesting. This may
mean that either these genes are highly mutable (which
may not be true since the disease is not so prevalent), or
Iranian population is so diverse. This diversity has many
historical proofs, which are beyond the scope of this
paper but it worth mentioning.
Conclusions
In conclusion, our investigation of 16 patients, and in
some cases including their families, revealed a number
of different mutations within the αIIb and β3 subunits
associated with causing GT. This vast number of differ-
ent mutations in different provinces of Iran indicates the
genetic heterogeneity in the studied group as well as in
GT in general. Further investigation on the prevalence
of each mutation from each ethnicity may reveal differ-
ent picture.
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